Raymond James Financial
GOSS icon

Raymond James Financial’s Gossamer Bio GOSS Stock Holding History

Raymond James Financial’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-270
Closed -$332 – 5682
2025
Q2 		$332 Buy
+270
New +$294 ﹤0.01% 6726

Other funds holding GOSS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Raymond James Financial's GOSS Position: Q3 2025 in Review

Raymond James Financial sold out of Gossamer Bio (GOSS) in Q3 2025, closing a stake of 270 shares — an estimated $332 sold.

Raymond James Financial first reported a position in GOSS in Q2 2025 and held it in 1 quarter. The position peaked at $332 in Q2 2025. 164 funds tracked by Wall St. Rank hold GOSS as of Q3 2025.

  • Raymond James Financial reported no remaining Gossamer Bio position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 270 Gossamer Bio shares in Q3 2025, an estimated $332.
  • Raymond James Financial first reported a position in Gossamer Bio in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Gossamer Bio position peaked at $332 in Q2 2025.
  • 164 funds tracked by Wall St. Rank held Gossamer Bio as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.